Loss of FXR protects against diet-induced obesity and accelerates liver carcinogenesis in ob/ob mice.

Farnesoid X receptor (FXR) is known to play important regulatory roles in bile acid, lipid, and carbohydrate metabolism. Aged (>12 months old) Fxr(-/-) mice also develop spontaneous liver carcinomas. In this report, we used three mouse models to investigate the role of FXR deficiency in obesity. As compared with low-density lipoprotein receptor (Ldlr) knockout (Ldlr(-/-)) mice, the Ldlr(-/-)Fxr(-/-) double-knockout mice were highly resistant to diet-induced obesity, which was associated with increased expression of genes involved in energy metabolism in the skeletal muscle and brown adipose tissue. Such a striking effect of FXR deficiency on obesity on an Ldlr(-/-) background led us to investigate whether FXR deficiency alone is sufficient to affect obesity. As compared with wild-type mice, Fxr(-/-) mice showed resistance to diet-induced weight gain. Interestingly, only female Fxr(-/-) mice showed significant resistance to diet-induced obesity, which was accompanied by increased energy expenditure in these mice. Finally, we determined the effect of FXR deficiency on obesity in a genetically obese and diabetic mouse model. We generated ob(-/-)Fxr(-/-) mice that were deficient in both Leptin and Fxr. On a chow diet, ob(-/-)Fxr(-/-) mice gained less body weight and had reduced body fat mass as compared with ob/ob mice. In addition, we observed liver carcinomas in 43% of young (<11 months old) Ob(-/-)Fxr(-/-) mice. Together these data indicate that loss of FXR prevents diet-induced or genetic obesity and accelerates liver carcinogenesis under diabetic conditions.

[1]  R. Roeder,et al.  Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia , 2008, The Journal of Experimental Medicine.

[2]  J. Girard,et al.  ChREBP, a transcriptional regulator of glucose and lipid metabolism. , 2007, Annual review of nutrition.

[3]  P. Edwards,et al.  Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) regulates triglyceride metabolism by activation of the nuclear receptor FXR , 2004 .

[4]  Yanqiao Zhang,et al.  FXR, a multipurpose nuclear receptor. , 2006, Trends in biochemical sciences.

[5]  M. Orešič,et al.  Farnesoid X Receptor Deficiency Improves Glucose Homeostasis in Mouse Models of Obesity , 2011, Diabetes.

[6]  E. Lam,et al.  FOXM1: From cancer initiation to progression and treatment. , 2012, Biochimica et biophysica acta.

[7]  M. Cooper,et al.  Hyperglycemia Induces a Dynamic Cooperativity of Histone Methylase and Demethylase Enzymes Associated With Gene-Activating Epigenetic Marks That Coexist on the Lysine Tail , 2008, Diabetes.

[8]  J. Ward,et al.  Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. , 2007, Carcinogenesis.

[9]  Masahiro Tohkin,et al.  Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis , 2000, Cell.

[10]  P. Edwards,et al.  FXR signaling in metabolic disease , 2008, FEBS letters.

[11]  Robert L. Sutherland,et al.  Cyclin D as a therapeutic target in cancer , 2011, Nature Reviews Cancer.

[12]  J. Repa,et al.  Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. , 2006, Cell metabolism.

[13]  B. Paigen,et al.  Leptin Promotes Biliary Cholesterol Elimination during Weight Loss in ob/ob Mice by Regulating the Enterohepatic Circulation of Bile Salts* , 2002, The Journal of Biological Chemistry.

[14]  R. Vigneri.  Diabetes: Diabetes therapy and cancer risk , 2009, Nature Reviews Endocrinology.

[15]  Yun Yen,et al.  Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. , 2007, Cancer research.

[16]  B. Staels,et al.  Role of bile acids and bile acid receptors in metabolic regulation. , 2009, Physiological reviews.

[17]  Songwen Zhang,et al.  Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. , 2009, Journal of hepatology.

[18]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.

[19]  Heidi R. Kast-Woelbern,et al.  Natural Structural Variants of the Nuclear Receptor Farnesoid X Receptor Affect Transcriptional Activation* , 2003, The Journal of Biological Chemistry.

[20]  Andy Wolfe,et al.  Increased Activation of the Wnt/β-Catenin Pathway in Spontaneous Hepatocellular Carcinoma Observed in Farnesoid X Receptor Knockout Mice , 2011, Journal of Pharmacology and Experimental Therapeutics.

[21]  E. Distrutti,et al.  Antiatherosclerotic effect of farnesoid X receptor. , 2009, American journal of physiology. Heart and circulatory physiology.

[22]  P. Edwards,et al.  FXR Deficiency Causes Reduced Atherosclerosis in Ldlr−/− Mice , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[23]  Stefan Westin,et al.  Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). , 2009, Journal of medicinal chemistry.

[24]  F. Kuipers,et al.  Enterohepatic Circulation of Bile Salts in Farnesoid X Receptor-deficient Mice , 2003, Journal of Biological Chemistry.

[25]  J. Auwerx,et al.  Lowering Bile Acid Pool Size with a Synthetic Farnesoid X Receptor (FXR) Agonist Induces Obesity and Diabetes through Reduced Energy Expenditure* , 2011, The Journal of Biological Chemistry.

[26]  D. Moore,et al.  Orphan receptor small heterodimer partner suppresses tumorigenesis by modulating cyclin D1 expression and cellular proliferation , 2008, Hepatology.

[27]  Justin R. Cross,et al.  ATP-Citrate Lyase Links Cellular Metabolism to Histone Acetylation , 2009, Science.

[28]  A. Morelli,et al.  A Farnesoid X Receptor-Small Heterodimer Partner Regulatory Cascade Modulates Tissue Metalloproteinase Inhibitor-1 and Matrix Metalloprotease Expression in Hepatic Stellate Cells and Promotes Resolution of Liver Fibrosis , 2005, Journal of Pharmacology and Experimental Therapeutics.

[29]  H. Towle,et al.  ChREBP•Mlx Is the Principal Mediator of Glucose-induced Gene Expression in the Liver* , 2006, Journal of Biological Chemistry.

[30]  M. Evans,et al.  Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR−/− and apoE−/− mice Published, JLR Papers in Press, January 27, 2009. , 2009, Journal of Lipid Research.

[31]  R. Evans,et al.  Anatomical Profiling of Nuclear Receptor Expression Reveals a Hierarchical Transcriptional Network , 2006, Cell.

[32]  J. Chiang,et al.  Aldo-keto reductase 1B7 is a target gene of FXR and regulates lipid and glucose homeostasis[S] , 2011, Journal of Lipid Research.

[33]  J. Auwerx,et al.  Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation , 2006, Nature.

[34]  L. Lanting,et al.  Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes , 2008, Proceedings of the National Academy of Sciences.